System that enables the measurement and verification of the radiation dose received by a patient following proton or helium ion therapy. It uses PET and the natural production of F-18 in tissues, offering applications in oncology and clinical safety.
A Penicillium chrysogenum strain has been modified to produce high yields of the antifungal protein PdAfpB, enabling the possibility to use this protein in agricultural, food and pharma industries.
Novel Folate Receptor alpha (FRα) binding peptides induce brain cell reprograming and rejuvenation, enhancing cognitive function in aged mice. These unique peptides are able cross the blood-brain barrier and specifically bind to neuroepithelial FRα.
Penicillium strain that produces a highly active antifungal protein (AFP), namely PeAfpA, which is effective against pathogenic and food spoilage fungi. The strain has also been modified to eliminate its antibiotic resistance genes, ensuring its safe use in agriculture, food, and biomedical applications.
A protein domain has been identified with the ability to direct membrane proteins and polypeptides of interest to the zymogen granules of pancreatic cells.
New compounds to treat parasitic diseases such as Chagas disease, leishmaniasis and trypanosomiasias. These derivatives act on a new target: G-cuadruplex DNA
Compounds useful as reversible visible-light-regulated antagonists for the localized and temporally restricted activation of beta-adrenoceptors, with application for the treatment of ocular diseases such as glaucoma.
New antiviral compound against HSV-1 and HSV-2 that can be used in combination with other drugs or to treat resistant strains to conventional antivirals.
Selective SGK1 kinase inhibitors, blood-brain barrier-permeable, as drug candidates for the treatment of neurodegenerative diseases (such as Parkinson’s or Alzheimer’s disease) or cardiovascular diseases (such as hypertension).
New family of compounds with demonstrated in vitro efficacy against intracellular parasites responsible for leishmaniasis and American trypanosomiasis or Chagas disease. Pharmacokinetic and toxicity studies have been conducted in rats, as well as preliminary efficacy studies in a murine model.